Get notified when COCH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received second Nasdaq notice for failure to maintain $1.00 minimum bid price and has been granted a final extension until November 16, 2026 to regain compliance or face potential delisting.
Envoy Medical gets second Nasdaq extension until Nov 2026, plans reverse split if needed
Filed May 22, 2026 · Period ending May 19, 2026 · ~1 min read
Key Changes
-
high
Nasdaq granted Envoy Medical an additional 180 days (until November 16, 2026) to regain compliance with the $1.00 minimum bid price requirement after the company failed to meet the initial May 18, 2026 deadline.
Item 3.01 verify on EDGAR → -
high
Company has notified Nasdaq of its intention to execute a reverse stock split if necessary to meet the bid price requirement, which would reduce share count and increase per-share price proportionally.
Item 3.01 verify on EDGAR → -
medium
The extension was granted because Envoy meets all other Nasdaq Capital Market listing requirements including market value of publicly held shares; only the bid price remains deficient.
Item 3.01 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade COCH commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · May 25, 2026 7:40 AM